A putative tumor suppressor, PTEN/MMAC1 gene at 10q23 was recently identi®ed and found to be mutated in many dierent human tumors. To determine the role of the PTEN/MMAC1 gene in lung cancer, we screened 34 small cell lung cancer (SCLC) cell lines, 10 SCLC tumors, 13 non-small cell lung cancer (NSCLC) cell lines and 10 NSCLC tumors using Denaturing HPLC (DHPLC) and direct sequencing methods. In SCLC, six (18%) of the cell lines and one of the primary tumor samples (10%) showed alterations of the PTEN/ MMAC1 gene including point mutations, small fragment deletions, and homozygous deletions. All of the point mutations and small fragment deletions were observed in hemizygously deleted cell lines. In contrast to SCLC, none of the NSCLC tumors or cell lines had mutations in the PTEN/MMAC1 gene. These data indicate that PTEN/MMAC1 mutations contribute to the pathogenesis and neoplastic evolution in SCLC but not in NSCLC.
Introduction
Carcinoma of the lung is leading cause of cancer mortality in men and women in the United States and other industrial countries (Parker et al., 1996) . Two major classes of human lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) which are delineated by clinical and biological features. SCLC accounts for approximately one-fourth of lung cancer cases and because of its aggressive biological behavior, has a relatively poor prognosis . Malignant transformation in SCLC is associated with a number of molecular alterations including the activation of the ras and myc oncogene families and disruptions of tumor suppressor genes including p53, Rb, CDKN2 and FHIT (Johnson and Kelley 1995; Giaccone, 1996; Sozzi et al., 1996) . Furthermore, cytogenetic studies have identi®ed consistent chromosomal loss in SCLC at chromosomes 3p, 4q, 5q, 10q, 13q and 17p Ried et al., 1994; Testa et al., 1997; Petersen et al., 1997) . Frequent loss of 10q sequences has also been observed in other kinds of tumors such as gliomas (Rempel et al., 1993; Leenstra et al., 1994) , melanoma (Herbst et al., 1994) and endometrial carcinomas (Peier et al., 1995) .
Recently, a putative tumor suppressor gene PTEN/ MMAC1 was identi®ed at 10q23.3 and found to be mutated or homozygously deleted in many kinds of malignant tumors such as glioma, prostate, breast and renal cancers Steck et al., 1997) . Studies also revealed that the PTEN/MMAC1 gene was highly mutated in glioblastomas Wang et al., 1997; Rasheed et al., 1997; Liu et al., 1997) , melanoma (Guldberg et al., 1997) , and endometrial carcinomas (Tashiro et al., 1997; Kong et al., 1997) . To examine whether the PTEN/MMAC1 gene is a target of the 10q loss in SCLC, and to understand the role of the PTEN/MMAC1 gene in various kinds of lung cancers, we screened 34 SCLC cell lines, 10 SCLC tissues, 13 NSCLC cell lines and 10 NSCLC tissues to detect alterations in the PTEN/ MMAC1 gene at the genomic DNA level. Denaturing high-performance liquid chromatography (DHPLC) and DNA sequencing were used to identify the mutations in this gene and a semi-quantitative multiplex polymerase chain reaction was used to detect and con®rm homozygous deletions.
Results
We analysed all 9 exons and their splice site junction sequences of the PTEN/MMAC1 gene in 47 lung cancer cell lines (34 SCLC and 13 NSCLC) and 20 lung cancer tumors (10 SCLC and 10 NSCLC). In the ®rst screening by DHPLC, we could not identify any unique DHPLC pro®les that showed heteroduplexes. This meant that all of the PCR products consisted of homoduplex DNA. Figure 1a represents the typical pro®le of homoduplex detected by DHPLC. In a monoclonal cell population as in a cell line, a homoduplex formation could also be observed when one allele is deleted and there is a point mutation in the retained allele. In order to determine if there was the case for any of the tested samples, we made a mixture of normal control PCR products and tumor PCR products, then screened for heteroduplexes by DHPLC. In the second screening, we found two heteroduplex pro®les. The sequencing of these samples (H735 and SHP77) revealed point mutations in one exon from each sample as shown in Table 1 . These results also demonstrate that these two cell lines were hemizygously deleted and had point mutations in the retained allele. The DHPLC pro®les and sequencing data in exon 7 of the SHP77 cells are shown in Figure 1b , c and e, while normal DHPLC pro®le and normal sequences are shown in Figure 1a and 1d as a control.
In the H446 cell line, the exon 4 PCR product showed a homoduplex pro®le, but with a minor shift in the ®rst screening by DHPLC and also showed one clear shifted band in agarose gel electrophoresis (data not shown), which suggested that this cell line had lost one allele and the remaining allele had a short deletion. Sequencing revealed a 46 bp deletion in exon 4 in this cell line ( Table 1 ). All of the NSCLC cell lines showed homoduplex pro®les in the second screening by DHPLC, so we concluded that there were no mutations in the 13 NSCLC cell lines.
We found that three cell lines (H774, H1436 and H1607 cell line) and one SCLC tissue had no PCR products in some exons by gel electrophoresis. To determine if these exons were homozygously deleted, we co-ampli®ed each of these exons in the presence of control primers for FBN1 exon 36 (Liu et al., 1996) using semi-quantitative PCR conditions, as described in Materials and methods. All the PCR reactions showed clear bands of the control FBN1 exon 36, but some of these reactions clearly showed no PCR ampli®cation of PTEN/MMAC1 exons. In the H774 cell line, there were no bands in the ampli®cations with primers for exon 1 through exon 5, but clear bands with primers for exons 6 through 9 (Figure 2 ). This suggested that this cell line was homozygously deleted from exon 1 to exon 5. We also identi®ed homozygous deletions from exon 1 to 6 in H1607 cells, from exon 3 to 9 in H1436 cells and exon 2 to 6 in one SCLC tumor sample ( Figure 2 ). We also performed semi-quantitative PCR in the NSCLC tumors, but did not identify any homozygous deletions in them (data not shown).
Discussion
Generally, tumor-associated mutations of tumor suppressor genes are recessive and, therefore both allele disruption of these genes are necessary to develop malignant phenotypes. Our observations demonstrate that both copies of the PTEN/MMAC1 gene were disrupted in 6 out of 34 SCLC cell lines and 1 out of The PTEN/MMAC1 gene was isolated from chromosomal region that showed frequent loss of heterozygosity (LOH) in many malignant tumors Steck et al., 1997) . The PTEN/MMAC1 gene has a homology to two kinds of proteins: tyrosine phosphatases and the cytoskeletal protein, tensin Steck et al., 1997) . Tyrosine phosphatases have been suggested to act as tumor suppressors because they could counter the action of tyrosine kinase, which phosphorylates tyrosine and stimulates cell growth (Pennisi, 1997) . Myers et al. reported that recombinant PTEN protein can dephosphorylate the phosphorylated serine, threonine and tyrosine residues, indicating that PTEN is a dual speci®city phosphatase (Myers et al., 1997) . The PTEN/MMAC1 gene also has homology to the cytoskeletal protein, tensin. Tensin maintains not only the structural integrity but also associates with focal adhesion, signal transduction and suppression of tumorigenesis (Lo et al., 1997) .
PTEN/MMAC1 gene mutations were detected in glioblastoma cell lines (13/42; 31%), prostate cancer cell lines (4/4; 100%), breast cancer cell lines (4/65; 6%), and primary glioblastomas (3/18; 17%) . Frequent mutation or homozygous deletions were also observed in melanoma cells lines (15/35; 26%) (Guldberg et al., 1997) and in primary endometrial carcinoma (16/36; 50%) (Tashiro et al., 1997) . We previously con®rmed that the PTEN/ MMAC1 gene is mutated in primary glioblastoma (17/63; 27%) by DHPLC method . Germline mutations of PTEN/MMAC1 have been identi®ed in Cowden disease patients that have high risks of breast, thyroid and skin cancers . However, only a small fraction of sporadic breast cancers showed the PTEN/MMAC1 gene abnormality (2/54, one patient had Cowden disease) (Rhei et al., 1997) , which indicates that PTEN/ MMAC1 gene is probably not involved in the carcinogenesis of the sporadic breast cancers.
Frequent deletion of 10q had been reported in SCLC (Levin et al., 1994 (Levin et al., , 1995 Ried et al., 1994; Schwendel et al., 1997; Petersen et al., 1997) . Schwendel et al also reported that loss in 10q23-qter is the third most frequently detected deletion after loss in 4q and 5q in SCLC . PTEN/MMAC1 is located within this region, and our mutation data strongly suggest the hypothesis that the PTEN/ MMAC1 gene is the target gene in 10q lesions. However, Levin et al. reported that 10q24-26 was a commonly deleted lesion by CGH (Levin et al., 1994) and Petersen et al. reported 10q24-qter as a consistently deleted region by LOH analysis . These data indicate that another important tumor suppressor gene(s) may be located distal to the PTEN/MMAC1 gene in 10q24-qter. The MXI1 gene at 10q 24-25 was reported as a candidate tumor suppressor gene in prostate cancer by mutation analysis (Eagle et al., 1995) and the MXI1 protein was reported to be a negative regulator of the myc oncogene (Schreiber-Agus et al., 1995). These reports suggest that MXI1 may be an attractive candidate tumor suppressor in prostate cancer, and possibly SCLC. However, the MXI1 gene was rarely mutated in prostate (Kawamata et al., 1996) and pancreatic cancers (Bartsch et al., 1996) , thus it is still unclear whether the MXI1 gene contributes to tumorigenesis as a suppressor gene.
Denaturing HPLC (DHPLC) is a novel automated mutation technology. It compares denatured and reannealed PCR amplicons and separates hetero-from homoduplexes on a micropellicular stationary phase under partially denaturing conditions. This technique has been applied in the mutation detection of the ATX1 gene in patients with familial hemiplegic migraine and episodic ataxia type-2 disease (Opho et al., 1996) and in the identi®cation of Single Nucleotide Polymorphisms (SNP's) on the Y chromosome for population studies (Underhill et al., 1996; 1997) . We have also used this technique to successfully detect PTEN mutations in primary glioblastomas and found that this gene was mutated in 27% of primary glioblastomas tested . In our analysis of the primary glioblastomas, we compared DHPLC with direct sequencing of the individual exons and found that this was a very accurate and robust technique for the rapid screening of mutations in a large number of samples (Liu et al., 1998) . The only limitation that we have observed in DHPLC is that there must be heteroduplexes present in the reannealed PCR mixture in order to detect an aberrant pro®le. Thus, it was necessary to mix the PCR products obtained from the cell lines with PCR products from the ampli®cation of normal DNA in order to have detectable heteroduplex.
In NSCLC, frequent chromosomal deletions were detected in 3p, 9p, and 17p, while relatively few 10q deletions were observed (Testa et al., 1997) . Our results Exon 2 ± 7 were homozygously deleted in one of 10 SCLC patients demonstrating that the PTEN/MMAC1 gene had no alterations in 13 NSCLC cell lines and 10 tumors, which suggest that the PTEN/MMAC1 gene does not contribute to NSCLC tumorigenesis. Obviously, NSCLC is a heterogeneous group of lung cancer including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, carcinoid and other rare tumor types. Cell-type speci®c mutation tests are warranted to better de®ne roles of various genes.
In summary our results suggest that the PTEN/ MMAC1 gene is the target of 10q22-23 loss in SCLC.
Materials and methods

Cell lines and the isolation of DNA
The cell lines and tumors used in this study are summarized in Table 2 . SCLC and NSCLC tumor cell lines were obtained from Dr Dean Edwards of the University of Colorado Cancer Center Tissue Culture Core and Dr Adi F Gazdar of University of Texas, Southwestern Medical Center. DNA from each sample were isolated and puri®ed as previously reported (James et al., 1988) . Tumor tissues of NSCLC were obtained from the patients diagnosed and operated at the Mayo Clinic (Rochester, MN). Ten primary SCLC samples were obtained from the biopsy or autopsy samples at Kyushu University, Japan. SCLC tissues were microdissected from the formalin-®xed, paran embedded slides corresponding to the cancer lesions observed in the hematoxylin and eosin staining.
PCR
PCR products used for DHPLC were generated in 50 ml reaction volumes that contained 100 ng of genomic DNA, 20 pmoles of forward and reverse primers for each PTEN/ MMAC1 exon (from 1 ± 9) (Steck et al., 1997) , 200 nM dNTPs (Perkin-Elmer, Foster City, CA), 0.25 ml of Taq polymerase (Amplitaq Gold: Perkin-Elmer), 10 mM TrisHCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , and 0.001% gelatin. PCR ampli®cations were for 35 cycles: 958C for 35 s, 558C for 30 s and 728C for 1 min (®nal extension at 728C for 10 min) followed by denaturation at 958C for 3 min and then gradual reannealing from 958C to 658C over a period of 30 min. Synthesized PCR products were analysed on 1.5% agarose gels. In case of SCLC tissues, each exon of PTEN was ampli®ed with dierent primer pairs and conditions as described previously (Risinger et al., 1997) , because more than 300 bp products were dicult to be ampli®ed from paran-embedded tissues. PCR products were analysed on 8% acrylamide gels and all the samples were direct sequenced as described below.
DHPLC analysis
DHPLC was carried out on an automated DHPLC system (Rainin) with a column containing alkylated nonporous poly(styrene divinylbenzene) particles (Sarasep, Inc). PCR products were examined for heteroduplexes by subjecting 4 ± 7 ml of each sample, containing approximately 100 ng of PTEN/MMAC1 exon sequence, to high performance liquid chromatography under conditions of partial denaturation (Oefner and Underhill, 1995; Liu et al., 1996) . The DHPLC method can separate DNA heteroduplexes from homoduplexes, so that we can determine which PCR products had sequence variations. For the ®rst screening, we ampli®ed the PTEN/MMAC1 exons and then separated the partially denatured PCR products by DHPLC to determine if there were any detectable heteroduplexes. However, in the tumor cell lines there is a possiblilty that, if the normal allele was deleted, the mutated second allele would appear as a homoduplex, and thus be scored as nonmutated. Thus, in our second round of screening, we added 10 ml of normal PCR product to 10 ml of PCR products from cell line DNA, denatured them, reannealed them together followed by testing for heteroduplexes by DHPLC. In the 10 primary NSCLC tumor samples, we did not add the normal PCR products as patients tumors generally contain normal cells.
DNA sequencing
PCR products that showed heteroduplex by DHPLC analysis and all the PTEN exons from SCLC tissues were cleaned with exonuclease and shrimp alkaline phosphatase based on the protocol provided by United States Biochemical. They were then mixed with 3.2 pmol of each forward or reverse primer of each exon and then sent for sequencing at Mayo Molecular Core Facilities in Mayo Clinic. Sequencing reactions were performed in a DNA Thermal Cycler 9600 (Perkin-Elmer Cetus) with¯uorescent terminations, and sequencing products were analysed on an ABI377 sequencer.
Semi-quantitative multiplex PCR
Miltiplex PCR reactions were performed under identical conditions as used for the heteroduplex detection and sequencing, except that ampli®cations were for 30 cycles. Every PTEN/MMAC1 exon was coampli®ed with control primer pairs speci®c for exon 36 of the ®brillin-1 (FBN1) gene (Liu et al., 1996) as an internal control. Standards were made by mixing normal DNA and PC-3 cell line DNA which is homoxygously deleted for the PTEN/ MMAC1 gene to estimate PTEN/MMAC1 gene losses of 0%, 25%, 50%, 75% and 100%, respectively (data not shown). Each PCR reaction product was resolved in 1.5% agarose gels or 8% acrylamide gel. Following electrophoresis, gels were stained with 0.5 mg/ml ethidium bromide in water for 30 min at room temperature and destained in deionized water for 30 min. In tumor samples, a homozygous deletion was de®ned by over a 75% reduction of the PTEN/MMAC1 PCR product compared to the control band. Band intensities were quanti®ed by the Gel Doc 1000 photodocumentation system (Bio-Rad) and its associated software (Molecular Analyst).
